A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma
Latest Information Update: 01 Feb 2024
At a glance
- Drugs FB 704A (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Oneness Biotech
- 25 Jan 2024 Planned End Date changed from 31 Dec 2022 to 30 Sep 2025.
- 25 Jan 2024 Planned primary completion date changed from 31 Jul 2022 to 30 Sep 2025.
- 27 Aug 2021 New trial record